Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis

Background Anti-human leukocyte antigen donor-specific antibodies (anti-HLA DSAs) are recognized as a major barrier to patients’ access to organ transplantation and the major cause of graft failure. The capacity of circulating anti-HLA DSAs to activate complement has been suggested as a potential bi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bouquegneau, Antoine (VerfasserIn) , Süsal, Caner (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: May 25, 2018
In: PLoS medicine
Year: 2018, Jahrgang: 15, Heft: 5
ISSN:1549-1676
DOI:10.1371/journal.pmed.1002572
Online-Zugang:Verlag, Volltext: https://doi.org/10.1371/journal.pmed.1002572
Verlag, Volltext: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002572
Volltext
Verfasserangaben:Antoine Bouquegneau, Charlotte Loheac, Olivier Aubert, Yassine Bouatou, Denis Viglietti, Jean-Philippe Empana, Camilo Ulloa, Mohammad Hassan Murad, Christophe Legendre, Denis Glotz, Annette M. Jackson, Adriana Zeevi, Stephan Schaub, Jean-Luc Taupin, Elaine F. Reed, John J. Friedewald, Dolly B. Tyan, Caner Süsal, Ron Shapiro, E. Steve Woodle, Luis G. Hidalgo, Jacqueline O’Leary, Robert A. Montgomery, Jon Kobashigawa, Xavier Jouven, Patricia Jabre, Carmen Lefaucheur, Alexandre Loupy

MARC

LEADER 00000caa a2200000 c 4500
001 1668625253
003 DE-627
005 20230427152748.0
007 cr uuu---uuuuu
008 190704s2018 xx |||||o 00| ||eng c
024 7 |a 10.1371/journal.pmed.1002572  |2 doi 
035 |a (DE-627)1668625253 
035 |a (DE-599)KXP1668625253 
035 |a (OCoLC)1341232072 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bouquegneau, Antoine  |e VerfasserIn  |0 (DE-588)1189863278  |0 (DE-627)1668625938  |4 aut 
245 1 0 |a Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival  |b a systematic review and meta-analysis  |c Antoine Bouquegneau, Charlotte Loheac, Olivier Aubert, Yassine Bouatou, Denis Viglietti, Jean-Philippe Empana, Camilo Ulloa, Mohammad Hassan Murad, Christophe Legendre, Denis Glotz, Annette M. Jackson, Adriana Zeevi, Stephan Schaub, Jean-Luc Taupin, Elaine F. Reed, John J. Friedewald, Dolly B. Tyan, Caner Süsal, Ron Shapiro, E. Steve Woodle, Luis G. Hidalgo, Jacqueline O’Leary, Robert A. Montgomery, Jon Kobashigawa, Xavier Jouven, Patricia Jabre, Carmen Lefaucheur, Alexandre Loupy 
264 1 |c May 25, 2018 
300 |a 25 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 04.07.2019 
520 |a Background Anti-human leukocyte antigen donor-specific antibodies (anti-HLA DSAs) are recognized as a major barrier to patients’ access to organ transplantation and the major cause of graft failure. The capacity of circulating anti-HLA DSAs to activate complement has been suggested as a potential biomarker for optimizing graft allocation and improving the rate of successful transplantations. Methods and findings To address the clinical relevance of complement-activating anti-HLA DSAs across all solid organ transplant patients, we performed a meta-analysis of their association with transplant outcome through a systematic review, from inception to January 31, 2018. The primary outcome was allograft loss, and the secondary outcome was allograft rejection. A comprehensive search strategy was conducted through several databases (Medline, Embase, Cochrane, and Scopus). A total of 5,861 eligible citations were identified. A total of 37 studies were included in the meta-analysis. Studies reported on 7,936 patients, including kidney (n = 5,991), liver (n = 1,459), heart (n = 370), and lung recipients (n = 116). Solid organ transplant recipients with circulating complement-activating anti-HLA DSAs experienced an increased risk of allograft loss (pooled HR 3.09; 95% CI 2.55–3.74, P = 0.001; I2 = 29.3%), and allograft rejection (pooled HR 3.75; 95% CI: 2.05–6.87, P = 0.001; I2 = 69.8%) compared to patients without complement-activating anti-HLA DSAs. The association between circulating complement-activating anti-HLA DSAs and allograft failure was consistent across all subgroups and sensitivity analyses. Limitations of the study are the observational and retrospective design of almost all included studies, the higher proportion of kidney recipients compared to other solid organ transplant recipients, and the inclusion of fewer studies investigating allograft rejection. Conclusions In this study, we found that circulating complement-activating anti-HLA DSAs had a significant deleterious impact on solid organ transplant survival and risk of rejection. The detection of complement-activating anti-HLA DSAs may add value at an individual patient level for noninvasive biomarker-guided risk stratification. Trial registration National Clinical Trial protocol ID: NCT03438058. 
650 4 |a Cardiac transplantation 
650 4 |a Complement system 
650 4 |a Heart-lung transplantation 
650 4 |a Liver transplantation 
650 4 |a Lung transplantation 
650 4 |a Renal transplantation 
650 4 |a Solid organ transplantation 
650 4 |a Transplant rejection 
700 1 |a Süsal, Caner  |e VerfasserIn  |0 (DE-588)102648037X  |0 (DE-627)726772763  |0 (DE-576)37182673X  |4 aut 
773 0 8 |i Enthalten in  |a Public Library of Science  |t PLoS medicine  |d Lawrence, Kan. : PLoS, 2004  |g 15(2018,5) Artikel-Nummer e1002572, 25 Seiten  |h Online-Ressource  |w (DE-627)470151471  |w (DE-600)2164823-2  |w (DE-576)273890131  |x 1549-1676  |7 nnas 
773 1 8 |g volume:15  |g year:2018  |g number:5  |g extent:25  |a Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival a systematic review and meta-analysis 
856 4 0 |u https://doi.org/10.1371/journal.pmed.1002572  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002572  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190704 
993 |a Article 
994 |a 2018 
998 |g 102648037X  |a Süsal, Caner  |m 102648037X:Süsal, Caner  |d 910000  |d 911600  |e 910000PS102648037X  |e 911600PS102648037X  |k 0/910000/  |k 1/910000/911600/  |p 18 
999 |a KXP-PPN1668625253  |e 3490942612 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["Public Library of Science"]},"id":{"eki":["470151471"],"zdb":["2164823-2"],"issn":["1549-1676"]},"origin":[{"publisher":"PLoS","dateIssuedKey":"2004","dateIssuedDisp":"2004-","publisherPlace":"Lawrence, Kan."}],"recId":"470151471","corporate":[{"display":"Public Library of Science","roleDisplay":"VerfasserIn","role":"aut"}],"language":["eng"],"disp":"Public Library of SciencePLoS medicine","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 20.11.2020"],"part":{"extent":"25","volume":"15","text":"15(2018,5) Artikel-Nummer e1002572, 25 Seiten","issue":"5","year":"2018"},"titleAlt":[{"title":"Medicine"}],"pubHistory":["1.2004 -"],"title":[{"title_sort":"PLoS medicine","title":"PLoS medicine"}]}],"physDesc":[{"extent":"25 S."}],"id":{"eki":["1668625253"],"doi":["10.1371/journal.pmed.1002572"]},"origin":[{"dateIssuedDisp":"May 25, 2018","dateIssuedKey":"2018"}],"name":{"displayForm":["Antoine Bouquegneau, Charlotte Loheac, Olivier Aubert, Yassine Bouatou, Denis Viglietti, Jean-Philippe Empana, Camilo Ulloa, Mohammad Hassan Murad, Christophe Legendre, Denis Glotz, Annette M. Jackson, Adriana Zeevi, Stephan Schaub, Jean-Luc Taupin, Elaine F. Reed, John J. Friedewald, Dolly B. Tyan, Caner Süsal, Ron Shapiro, E. Steve Woodle, Luis G. Hidalgo, Jacqueline O’Leary, Robert A. Montgomery, Jon Kobashigawa, Xavier Jouven, Patricia Jabre, Carmen Lefaucheur, Alexandre Loupy"]},"language":["eng"],"recId":"1668625253","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 04.07.2019"],"title":[{"subtitle":"a systematic review and meta-analysis","title":"Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival","title_sort":"Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival"}],"person":[{"roleDisplay":"VerfasserIn","display":"Bouquegneau, Antoine","role":"aut","family":"Bouquegneau","given":"Antoine"},{"given":"Caner","family":"Süsal","role":"aut","roleDisplay":"VerfasserIn","display":"Süsal, Caner"}]} 
SRT |a BOUQUEGNEACOMPLEMENT2520